bioMerieux (OTCMKTS:BMXMF) Shares Gap Down – Time to Sell?

bioMerieux (OTCMKTS:BMXMF) shares gapped down before the market opened on Monday . The stock had previously closed at $84.0750, but opened at $78.16. bioMerieux shares last traded at $78.16, with a volume of 65 shares traded.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on BMXMF shares. Piper Sandler began coverage on bioMerieux in a research note on Thursday. They set a “neutral” rating for the company. Zacks Research raised bioMerieux to a “hold” rating in a research note on Tuesday, April 28th. Deutsche Bank Aktiengesellschaft lowered shares of bioMerieux from a “buy” rating to a “hold” rating in a research report on Friday, April 24th. Finally, UBS Group lowered shares of bioMerieux from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Five research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock has an average rating of “Hold”.

bioMerieux Trading Up 1.1%

The company has a current ratio of 2.39, a quick ratio of 1.48 and a debt-to-equity ratio of 0.08. The business has a 50-day moving average price of $90.87 and a 200-day moving average price of $109.35.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.